the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Uterus/ Endometrium Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
IRB14-0160 Moroney, John GOG 286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC #91485) Versus Paclitaxel/Carboplatin/ Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Details
Phase II
Study No PI Title
IRB16-1294 Fleming, Gini A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients with MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer
IRB15-0196 Lee, Nita A Phase 1/2A Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, A Dual Receptor Tyrosine Kinase Inhibitor, in Subjects with Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer Details
CIRB15-1357 Luke, Jason EAY131: Molecular Analysis for Therapy Choice (MATCH) Details
IRB14-0160 Moroney, John GOG 286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC #91485) Versus Paclitaxel/Carboplatin/ Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer Details
Phase I
Study No PI Title
IRB16-1743 Ratain, Mark An Open Label Phase I, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies
IRB15-0196 Lee, Nita A Phase 1/2A Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, A Dual Receptor Tyrosine Kinase Inhibitor, in Subjects with Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer Details
IRB16-0257 Luke, Jason A Two Part, Phase I, Multicenter, Open-Label Study of TRX518 in Adults with Advanced Solid Tumors Part A: A Dose-Escalation Study of Multi-dose TRX518 Monotherapy Part B: An Expansion Cohort of Multi-dose TRX518 Monotherapy at the Maximum Tolerated Dose Details
Others
Study No PI Title
IRB16-0606 Romero, Iris Stand Up To Cancer: WISP Trial (Women Choosing Surgical Prevention)
12-1157 Grushko, Tatyana Topoisomerase 2A (TOPO2A) Amplification/Overexpression and Other Predictive/Prognostic Markers in Women with Endometrial Cancer
10-627-A GRUSHKO, TATYANA GOG 8013: Topoisomerase 2-Alpha (TOPO2A) Genomic Alterations and Immunohistochemical Expression As Well As Chromosome 17 Polysomy in Advanced or Recurrent Endometrial Carcinoma Treated with Anthracycline-Based Therapy Details
09-123-B Hasan, Yasmin Long Term Database Collection for Endometrial Cancer


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .